• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

包载水飞蓟素的壳聚糖纳米粒(水飞蓟素-壳聚糖纳米粒)对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的抗病毒活性(及研究)

Antiviral activity of chitosan nanoparticles encapsulating silymarin (Sil-CNPs) against SARS-CoV-2 ( and study).

作者信息

Loutfy Samah A, Abdel-Salam Ahmed I, Moatasim Yassmin, Gomaa Mokhtar R, Abdel Fattah Nasra F, Emam Merna H, Ali Fedaa, ElShehaby Hasnaa A, Ragab Eman A, Alam El-Din Hanaa M, Mostafa Ahmed, Ali Mohamed A, Kasry Amal

机构信息

Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute (NCI), Cairo University Fom El-Khalig 11796 Cairo Egypt

Nanotechnology Research Center (NTRC), The British University in Egypt El-Shorouk City, Suez Desert Road P. O. Box 43 Cairo 11837 Egypt

出版信息

RSC Adv. 2022 May 25;12(25):15775-15786. doi: 10.1039/d2ra00905f. eCollection 2022 May 23.

DOI:10.1039/d2ra00905f
PMID:35685696
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9132606/
Abstract

To develop a specific treatment against COVID-19, we investigated silymarin-chitosan nanoparticles (Sil-CNPs) as an antiviral agent against SARS-CoV-2 using and approaches. Docking of Sil and CNPs was carried out against SARS-CoV-2 spike protein using AutoDock Vina. CNPs and Sil-CNPs were prepared by the ionic gelation method and characterized by TEM, FT-IR, zeta analysis, and the membrane diffusion method to determine the drug release profile. Cytotoxicity was tested on both Vero and Vero E6 cell lines using the MTT assay. Minimum binding energies with spike protein and ACE2 were -6.6, and -8.0 kcal mol for CNPs, and -8.9, and -9.7 kcal mol for Sil, respectively, compared to -6.6 and -8.4 kcal mol respectively for remdesivir (RMV). CNPs and Sil-CNPs were prepared at sizes of 29 nm and 82 nm. The CC50 was 135, 35, and 110 μg mL for CNPs, Sil, and Sil-CNPs, respectively, on Vero E6. The IC50 was determined at concentrations of 0.9, 12 and 0.8 μg mL in virucidal/replication assays for CNPs, Sil, and Sil-CNPs respectively using crystal violet. These results indicate antiviral activity of Sil-CNPs against SARS-CoV-2.

摘要

为开发针对COVID-19的特异性治疗方法,我们使用[具体方法1]和[具体方法2]研究了水飞蓟素-壳聚糖纳米颗粒(Sil-CNPs)作为抗SARS-CoV-2的抗病毒剂。使用AutoDock Vina对水飞蓟素(Sil)和壳聚糖纳米颗粒(CNPs)与SARS-CoV-2刺突蛋白进行对接。通过离子凝胶法制备CNPs和Sil-CNPs,并通过透射电子显微镜(TEM)、傅里叶变换红外光谱(FT-IR)、zeta分析和膜扩散法对其进行表征,以确定药物释放曲线。使用MTT法在Vero和Vero E6细胞系上测试细胞毒性。与瑞德西韦(RMV)分别为-6.6和-8.4 kcal/mol相比,CNPs与刺突蛋白和血管紧张素转换酶2(ACE2)的最小结合能分别为-6.6和-8.0 kcal/mol,Sil分别为-8.9和-9.7 kcal/mol。制备的CNPs和Sil-CNPs尺寸分别为29 nm和82 nm。在Vero E6细胞上,CNPs、Sil和Sil-CNPs的半数细胞毒性浓度(CC50)分别为135、35和110 μg/mL。在使用结晶紫的杀病毒/复制试验中,CNPs、Sil和Sil-CNPs的半数抑制浓度(IC50)分别测定为0.9、12和0.8 μg/mL。这些结果表明Sil-CNPs对SARS-CoV-2具有抗病毒活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/b1b4847e8a9c/d2ra00905f-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/4a71b07c885c/d2ra00905f-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/acc662a98f56/d2ra00905f-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/d8c6f94ca402/d2ra00905f-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/9f64459b8e78/d2ra00905f-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/863777f17697/d2ra00905f-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/fba729354bd3/d2ra00905f-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/b1b4847e8a9c/d2ra00905f-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/4a71b07c885c/d2ra00905f-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/acc662a98f56/d2ra00905f-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/d8c6f94ca402/d2ra00905f-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/9f64459b8e78/d2ra00905f-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/863777f17697/d2ra00905f-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/fba729354bd3/d2ra00905f-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/824a/9132606/b1b4847e8a9c/d2ra00905f-f7.jpg

相似文献

1
Antiviral activity of chitosan nanoparticles encapsulating silymarin (Sil-CNPs) against SARS-CoV-2 ( and study).包载水飞蓟素的壳聚糖纳米粒(水飞蓟素-壳聚糖纳米粒)对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的抗病毒活性(及研究)
RSC Adv. 2022 May 25;12(25):15775-15786. doi: 10.1039/d2ra00905f. eCollection 2022 May 23.
2
Green Synthesis of Silymarin-Chitosan Nanoparticles as a New Nano Formulation with Enhanced Anti-Fibrotic Effects against Liver Fibrosis.水飞蓟宾-壳聚糖纳米粒的绿色合成:一种新型纳米制剂,具有增强的抗肝纤维化作用。
Int J Mol Sci. 2022 May 12;23(10):5420. doi: 10.3390/ijms23105420.
3
Establishment of in-house assay for screening of anti-SARS-CoV-2 protein inhibitors.建立用于筛选抗SARS-CoV-2蛋白抑制剂的内部检测方法。
AMB Express. 2024 Sep 16;14(1):104. doi: 10.1186/s13568-024-01739-8.
4
[Salvianolic acid B and its magnesium salt inhibit SARS-CoV-2 infection of Vero-E6 cells by blocking spike protein-mediated membrane fusion].[丹酚酸B及其镁盐通过阻断刺突蛋白介导的膜融合抑制SARS-CoV-2对Vero-E6细胞的感染]
Nan Fang Yi Ke Da Xue Xue Bao. 2021 Apr 20;41(4):475-482. doi: 10.12122/j.issn.1673-4254.2021.04.01.
5
In vitro efficacy of polymer coated miltefosine drug against leishmania tropica.聚合物包被的米替福新药物对热带利什曼原虫的体外疗效。
J Parasit Dis. 2022 Jun;46(2):366-376. doi: 10.1007/s12639-021-01452-4. Epub 2021 Sep 23.
6
Exploring the therapeutic potential of Thai medicinal plants: in vitro screening and in silico docking of phytoconstituents for novel anti-SARS-CoV-2 agents.探索泰国药用植物的治疗潜力:用于新型抗 SARS-CoV-2 药物的植物成分的体外筛选和计算机对接。
BMC Complement Med Ther. 2024 Jul 19;24(1):274. doi: 10.1186/s12906-024-04586-z.
7
Antibacterial Activity of Chitosan Nanoparticles Against Pathogenic .壳聚糖纳米粒子对病原菌的抗菌活性。
Int J Nanomedicine. 2020 Oct 13;15:7877-7887. doi: 10.2147/IJN.S272736. eCollection 2020.
8
Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.基于甘草酸的抑制剂对新型冠状病毒2型(SARS-CoV-2)ACE2宿主受体的分子筛选
J Mol Model. 2021 Jun 24;27(7):206. doi: 10.1007/s00894-021-04816-y.
9
Anticancer efficacy of 6-thioguanine loaded chitosan nanoparticles with or without curcumin.载 6-巯基嘌呤壳聚糖纳米粒联合或不联合姜黄素的抑瘤作用。
Int J Biol Macromol. 2020 Apr 1;148:704-714. doi: 10.1016/j.ijbiomac.2020.01.117. Epub 2020 Jan 15.
10
Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro.阿昔莫司钠对 SARS-CoV-2 的体外抗病毒和病毒杀灭活性。
Antiviral Res. 2021 Jul;191:105089. doi: 10.1016/j.antiviral.2021.105089. Epub 2021 May 16.

引用本文的文献

1
Exploring marine glycans: structure, function, and the frontier of chemical synthesis.探索海洋聚糖:结构、功能及化学合成前沿
RSC Chem Biol. 2025 Jun 4. doi: 10.1039/d5cb00090d.
2
Phytochemical-based nanosystems: recent advances and emerging application in antiviral photodynamic therapy.基于植物化学物质的纳米系统:抗病毒光动力疗法的最新进展与新兴应用
Nanomedicine (Lond). 2025 Feb;20(4):401-416. doi: 10.1080/17435889.2025.2452151. Epub 2025 Jan 23.
3
Applications of Chitosan in Prevention and Treatment Strategies of Infectious Diseases.

本文引用的文献

1
Nanoparticle-Based Strategies to Combat COVID-19.基于纳米颗粒的抗击新冠病毒策略
ACS Appl Nano Mater. 2020 Aug 25;3(9):8557-8580. doi: 10.1021/acsanm.0c01978. eCollection 2020 Sep 25.
2
Self-crosslinked chitosan/κ-carrageenan-based biomimetic membranes to combat diabetic burn wound infections.用于对抗糖尿病烧伤伤口感染的自交联壳聚糖/κ-卡拉胶基仿生膜
Int J Biol Macromol. 2022 Feb 1;197:157-168. doi: 10.1016/j.ijbiomac.2021.12.100. Epub 2021 Dec 27.
3
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
壳聚糖在传染病防治策略中的应用
Pharmaceutics. 2024 Sep 13;16(9):1201. doi: 10.3390/pharmaceutics16091201.
4
Anti-Coronavirus Activity of Chitosan-Stabilized Liposomal Nanocarriers Loaded with Natural Extracts from Bulgarian Flora.负载保加利亚植物天然提取物的壳聚糖稳定脂质体纳米载体的抗冠状病毒活性
Life (Basel). 2024 Sep 19;14(9):1180. doi: 10.3390/life14091180.
5
Establishment of in-house assay for screening of anti-SARS-CoV-2 protein inhibitors.建立用于筛选抗SARS-CoV-2蛋白抑制剂的内部检测方法。
AMB Express. 2024 Sep 16;14(1):104. doi: 10.1186/s13568-024-01739-8.
6
Prospects of Innovative Therapeutics in Combating the COVID-19 Pandemic.创新疗法抗击新冠疫情的前景
Mol Biotechnol. 2025 Jul;67(7):2598-2606. doi: 10.1007/s12033-024-01240-4. Epub 2024 Aug 1.
7
Chitosan-Based Structural Color Films for Humidity Sensing with Antiviral Effect.具有抗病毒作用的用于湿度传感的壳聚糖基结构色薄膜
Nanomaterials (Basel). 2024 Feb 13;14(4):351. doi: 10.3390/nano14040351.
8
The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2.生物材料在新型冠状病毒疫苗、治疗及检测中的应用
ACS Omega. 2024 Jan 26;9(5):5175-5192. doi: 10.1021/acsomega.3c08326. eCollection 2024 Feb 6.
9
Potent Antiviral Activity of Vitamin B12 against Severe Acute Respiratory Syndrome Coronavirus 2, Middle East Respiratory Syndrome Coronavirus, and Human Coronavirus 229E.维生素B12对严重急性呼吸综合征冠状病毒2、中东呼吸综合征冠状病毒和人冠状病毒229E具有强大的抗病毒活性。
Microorganisms. 2023 Nov 15;11(11):2777. doi: 10.3390/microorganisms11112777.
10
CD44 targeted delivery of oncolytic Newcastle disease virus encapsulated in thiolated chitosan for sustained release in cervical cancer: a targeted immunotherapy approach.巯基化壳聚糖包载的靶向 CD44 的溶瘤新城疫病毒用于宫颈癌的持续释放:一种靶向免疫治疗方法。
Front Immunol. 2023 May 22;14:1175535. doi: 10.3389/fimmu.2023.1175535. eCollection 2023.
莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
4
Nano-therapeutic strategies to target coronavirus.靶向冠状病毒的纳米治疗策略。
View (Beijing). 2021 Jun;2(3):20200155. doi: 10.1002/VIW.20200155. Epub 2021 Mar 9.
5
Extraction of chlorophyll and carotenoids loaded into chitosan as potential targeted therapy and bio imaging agents for breast carcinoma.壳聚糖负载的叶绿素和类胡萝卜素的提取作为乳腺癌潜在的靶向治疗和生物成像试剂。
Int J Biol Macromol. 2021 Jul 1;182:1150-1160. doi: 10.1016/j.ijbiomac.2021.03.189. Epub 2021 Apr 15.
6
Phyto-pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for COVID-19, based on its promising immunomodulatory, anti-coagulant and anti-viral property.水飞蓟宾的植物药理学视角:基于其有前景的免疫调节、抗凝和抗病毒特性,作为 COVID-19 的潜在预防或治疗剂。
Phytother Res. 2021 Aug;35(8):4246-4257. doi: 10.1002/ptr.7084. Epub 2021 Apr 4.
7
Chitosan-Based Nanoparticles Against Viral Infections.壳聚糖纳米粒子对抗病毒感染。
Front Cell Infect Microbiol. 2021 Mar 17;11:643953. doi: 10.3389/fcimb.2021.643953. eCollection 2021.
8
Underscoring the immense potential of chitosan in fighting a wide spectrum of viruses: A plausible molecule against SARS-CoV-2?强调壳聚糖在对抗多种病毒方面的巨大潜力:一种对抗 SARS-CoV-2 的合理分子?
Int J Biol Macromol. 2021 May 15;179:33-44. doi: 10.1016/j.ijbiomac.2021.02.090. Epub 2021 Feb 16.
9
FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2.经美国食品药品监督管理局批准的、对严重急性呼吸综合征冠状病毒2具有强大体外抗病毒活性的药物。
Pharmaceuticals (Basel). 2020 Dec 4;13(12):443. doi: 10.3390/ph13120443.
10
Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19.地高辛和哇巴因抗 SARS-CoV-2 感染的抗病毒活性及其对 COVID-19 的意义。
Sci Rep. 2020 Oct 1;10(1):16200. doi: 10.1038/s41598-020-72879-7.